24 308

Cited 22 times in

Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

Authors
Uhm, JE; Park, BB; Ahn, MJ; Lee, J; Ahn, JS; Kim, SW; Kim, HT; Lee, JS; Kang, JH; Cho, JY; Song, HS; Park, SH; Sohn, CH; Shin, SW; Choi, JH; Park, K
Citation
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 4(9):1136-1143, 2009
Journal Title
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN
1556-08641556-1380
Abstract
BACKGROUND: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good tolerability in non-small cell lung cancer (NSCLC). In particular, higher response rates have been reported in Asian patients than in Western patients. The aim of this study conducted by the Korean Cancer Study Group was to evaluate the efficacy and tolerability of erlotinib monotherapy as a palliative treatment for advanced NSCLC patients in Korea. PATIENTS AND METHODS: Patients with histologically or cytologically confirmed stage IIIB or IV NSCLC including recurrent or metastatic disease, with performance status from 0 to 3, were eligible either if they had received any anticancer treatment except epidermal growth factor receptor inhibitors or if they were unsuitable for chemotherapy because of poor performance status. Enrolled patients were treated with oral erlotinib at a dose of 150 mg daily until disease progression or development of intolerable toxicity. RESULTS: A total of 120 patients were enrolled between January 2005 and May 2006. Forty-four patients (36.7%) were female and 72 patients were current or former smoker. Fifty percent of patients had received one prior palliative chemotherapy regimens and 34.2% had two or more prior palliative regimens. The overall tumor response rate was 24.2% (95% confidence interval [CI], 16.8-32.8%) with 4 complete responses and 25 partial responses, and the disease control rate was 56.7%. The favorable clinical variables for tumor response were female (P = 0.001), never smokers (P = 0.041), and adenocarcinoma (P = 0.001). The most common adverse event was skin rash (78% of which grade 3 or 4 skin rash occurred in 13.3% of the patients). With a median follow-up of 23.6 months, the median time to progression was 2.7 months (95% CI, 2.2-3.2), and the median overall survival was 12.9 months (95% CI, 6.9-18.8). By multivariate analysis, female and development of skin rash were significantly associated with longer time to progression and overall survival. CONCLUSION: Erlotinib monotherapy showed significant antitumor activity and an acceptable tolerability profile as a palliative treatment in advanced NSCLC patients in Korea, especially in females, never smokers, and patients with adenocarcinoma histology.
MeSH terms
AdultAgedAged, 80 and overAsian Continental Ancestry GroupCarcinoma, Non-Small-Cell Lung/drug therapy*Carcinoma, Non-Small-Cell Lung/ethnologyCarcinoma, Non-Small-Cell Lung/mortalityFemaleHumansLung Neoplasms/drug therapy*Lung Neoplasms/ethnologyLung Neoplasms/mortalityMaleMiddle AgedMutationNeoplasm StagingProspective StudiesProtein Kinase Inhibitors/therapeutic use*Quinazolines/adverse effectsQuinazolines/therapeutic use*Receptor, Epidermal Growth Factor/antagonists & inhibitors*Receptor, Epidermal Growth Factor/genetics
DOI
10.1097/JTO.0b013e3181b270a7
PMID
19687764
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
최진혁
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse